Spero Therapeutics (NASDAQ:SPRO – Get Free Report) had its price objective upped by research analysts at HC Wainwright from $5.00 to $6.00 in a research note issued to investors on Monday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 430.97% from […]

Ovid Therapeutics (NASDAQ:OVID – Free Report) had its price objective increased by HC Wainwright from $4.00 to $5.00 in a report released on Friday, Marketbeat.com reports. They currently have a buy rating on the stock. A number of other equities analysts have also weighed in on the company. Roth Capital reiterated a “buy” rating and […]

BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Free Report) had its target price decreased by Leerink Partners to $27.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock. A number of other research firms have also recently commented on BBOT. Weiss Ratings restated a “sell (d-)” rating on […]

Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lifted by Guggenheim from $135.00 to $170.00 in a report released on Monday, Marketbeat Ratings reports. Guggenheim currently has a buy rating on the stock. Several other analysts have also recently commented on the company. B. Riley Financial raised their target price on Kymera Therapeutics […]

Maplight Therapeutics (NASDAQ:MPLT – Free Report) had its target price trimmed by Needham & Company LLC from $45.00 to $43.00 in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock. Other equities analysts also recently issued research reports about the stock. Wolfe Research […]